Cargando…

OTME-4. IDH mutated gliomas promote epileptogenesis via D-2-hydroxyglutarate dependent mTOR hyperactivation

Epilepsy in the context of brain tumors provides a great burden in these patients, yet mechanisms underlying this process are poorly understood. It has been demonstrated that isocitrate dehydrogenase (IDH) mutations are an independent factor in epileptogenesis in patients with low grade gliomas. Her...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mortazavi, Armin, Fayed, Islam, Bachani, Muzna, Maric, Dragan, Dowdy, Tyrone, Larion, Mioara, Ksendzovsky, Alexander, Zaghloul, Kareem
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8255454/ http://dx.doi.org/10.1093/noajnl/vdab070.055

Ejemplares similares

DDRE-27. IDH MUTATED GLIOMAS PROMOTE EPILEPTOGENESIS VIA D-2-HYDROXYGLUTARATE DEPENDENT MTOR HYPERACTIVATION
por: Mortazavi, Armin, et al.
Publicado: (2021)

Differential metabolic alterations in IDH1 mutant vs. wildtype glioma cells promote epileptogenesis through distinctive mechanisms
por: McAfee, Darrian, et al.
Publicado: (2023)

BIMG-10. IDH1 MUTATIONS INDUCE ORGANELLE DEFECTS VIA DYSREGULATED PHOSPHOLIPIDS
por: Yamasaki, Tomohiro, et al.
Publicado: (2021)

DDRE-20. TARGETING SPHINGOLIPID PATHWAY REVEALS VULNERABILITY IN IDH1(MUT) GLIOMA
por: Dowdy, Tyrone, et al.
Publicado: (2021)

Sphingolipid Pathway as a Source of Vulnerability in IDH1(mut) Glioma
por: Dowdy, Tyrone, et al.
Publicado: (2020)

Targeting the Sphingolipid Rheostat in Gliomas
por: Zaibaq, Faris, et al.
Publicado: (2022)

CBMS-5 STEAROYL-COA DESATURASE INHIBITOR INDUCES APOPTOSIS VIA ENHANCING LIPOLYSIS IN IDH MUTANT GLIOMA
por: Zhang, Lumin, et al.
Publicado: (2022)

Metabolic Landscape of a Genetically Engineered Mouse Model of IDH1 Mutant Glioma
por: Ruiz-Rodado, Victor, et al.
Publicado: (2020)

Metabolic biomarkers of radiotherapy response in plasma and tissue of an IDH1 mutant astrocytoma mouse model
por: Ruiz-Rodado, Victor, et al.
Publicado: (2022)

DDRE-01. METABOLIC PLASTICITY AND HETEROGENEITY IN IDH1MUT CELL LINES PRODUCES RESISTANCE TO GLUTAMINASE INHIBITION BY CB839
por: Larion, Mioara, et al.
Publicado: (2021)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

Responsive Neurostimulation for Seizure Control: Current Status and Future Directions
por: Boddeti, Ujwal, et al.
Publicado: (2022)

2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients
por: Choi, Changho, et al.
Publicado: (2012)

The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
por: Wang, Tian-Xiang, et al.
Publicado: (2019)

Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas
por: Riviere-Cazaux, Cecile, et al.
Publicado: (2023)

IDH1 mutations induce organelle defects via dysregulated phospholipids
por: Lita, Adrian, et al.
Publicado: (2021)

D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
por: Akbay, Esra A., et al.
Publicado: (2014)

Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity
por: Chittaranjan, Suganthi, et al.
Publicado: (2014)

Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas
por: Leather, Thomas, et al.
Publicado: (2017)

(R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas
por: Richardson, Leland G., et al.
Publicado: (2019)

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
por: Han, Sue, et al.
Publicado: (2020)

The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway
por: Carbonneau, Mélissa, et al.
Publicado: (2016)

DDRE-08. NRF2/GLUTATHIONE METABOLISM AS A NOVEL THERAPEUTIC TARGET FOR IDH1-MUTATED GLIOMA
por: Liu, Yang, et al.
Publicado: (2021)

Characterization of cancer-associated IDH2 mutations that differ in tumorigenicity, chemosensitivity and 2-hydroxyglutarate production
por: Kotredes, Kevin P., et al.
Publicado: (2019)

Metabolic plasticity of IDH1-mutant glioma cell lines is responsible for low sensitivity to glutaminase inhibition
por: Ruiz-Rodado, Victor, et al.
Publicado: (2020)

Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner
por: Viswanath, Pavithra, et al.
Publicado: (2018)

Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry
por: Longuespée, Rémi, et al.
Publicado: (2018)

DDRE-16. CYSTEINE IS AN ESSENTIAL AMINO ACID IN GLIOMAS
por: Ruiz-Rodado, Victor, et al.
Publicado: (2021)

The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo
por: Suijker, Johnny, et al.
Publicado: (2015)

Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Fiehn, Oliver, et al.
Publicado: (2016)

Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate
por: Showalter, Megan Reed, et al.
Publicado: (2017)

Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy
por: Larion, Mioara, et al.
Publicado: (2018)

OTME-14. TGF-beta signaling in microtube formation of glioblastoma
por: Storevik, Simon, et al.
Publicado: (2021)

D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth
por: Ma, Shenghong, et al.
Publicado: (2015)

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
por: Andronesi, Ovidiu C., et al.
Publicado: (2018)

Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas
por: Autry, Adam W., et al.
Publicado: (2022)

The Potential Use of Pharmacological Agents to Modulate Orthodontic Tooth Movement (OTM)
por: Kouskoura, Thaleia, et al.
Publicado: (2017)

OTME-2. Regulation of chromatin accessibility in the hypoxic tumor microenvironment of glioblastoma
por: Dzwigonska, Monika, et al.
Publicado: (2021)

The Roles of 2-Hydroxyglutarate
por: Du, Xin, et al.
Publicado: (2021)

The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
por: Mu, Luyan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_387pqq4amjodp33nh1q5u770o8